Indivior Pharmaceuticals, Inc 6-K, filed Mar 18, 2024
Indivior Pharmaceuticals, Inc. (INDV)
6-K
2024-03-18
For: 2024-03-18
View Original
Added on
July 07, 2026
About this 6-K
Indivior Pharmaceuticals, Inc filed this 6-K on March 18, 2024.
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
Date: March 18, 2024
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ☐
|
|
EXHIBIT INDEX
|
Exhibit No.
|
Description
of Exhibit
|
|
99.1
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Indivior PLC
|
|
Date: March 18,
2024
|
/s/
Kathryn Hudson
|
|
|
Name:
Kathryn Hudson
|
|
|
Title:
Company Secretary
|
Exhibit
99.1
INDIVIOR PLC (THE 'COMPANY')
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES ('PDMR') AND PERSONS
CLOSELY ASSOCIATED WITH THEM
The Company announces that on March 15, 2024, an award over 7,140
Ordinary Shares of $0.10 each ('Shares') vested in favour of Ryan
Preblick, a PDMR and the Chief Financial Officer of the Company,
under the Indivior Deferred Bonus Plan 2018 (the 'DBP'). This
award was granted on March 15, 2022 and vested following the end of
the two-year deferral period. The vesting of the award was not
subject to performance conditions. The vesting of this
award was settled on a net settled basis, resulting in the delivery
of Shares in the amount set out below.
|
Name of PDMR
|
Number of vested Shares
|
Number of Shares delivered
|
|
Ryan Preblick
|
7,140
|
3,920
|
Following
this transaction, Ryan Preblick has an interest in 68,386 Shares in
the Company.
This notification is made in accordance with the requirements
of the UK Market Abuse Regulation.
Kathryn Hudson
Company Secretary
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
||
|
a)
|
Name
|
Ryan Preblick
|
|
|
2
|
Reason for the notification
|
||
|
a)
|
Position/status
|
Director / PDMR - Chief Financial Officer
|
|
|
b)
|
Initial notification /Amendment
|
Initial notification
|
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
Indivior PLC
|
|
|
b)
|
LEI
|
213800V3NCQTY7IED471
|
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
||
|
a)
|
Description of the financial instrument, type of
instrument
Identification code
|
Ordinary Shares of US$0.50
GB00BN4HT335
|
|
|
b)
|
Nature of the transaction
|
Delivery of Shares on Vesting of an award granted under the
DBP.
|
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
N/A
|
3,920
|
||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
|
|
e)
|
Date of the transaction
|
March 15, 2024
|
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
|
Indivior PLC's Legal Entity Identifier code is
213800V3NCQTY7IED471.